Efficacy of La Roche-Posay products in the treatment of skin toxicity induced by antitumor therapy: a prospective study

Kruglova L.S., Zhuravlev S.V., Shatokhina E.A., Gryazeva N.V.

1) Central State Medical Academy of the Administrative Department of the President of the Russian Federation, Moscow, Russia; 2) Clinical Hospital No. 1 (Volynskaya) of the Administrative Department of the President of the Russian Federation, Moscow, Russia; 3) Medical Research and Educational Institute, Lomonosov Moscow State University, Moscow, Russia

Objective: Evaluation of the dynamics of the severity of skin xerosis, fissuring, and eczematization symptoms in cancer patients treated with La Roche-Posay emollients over a 4-week period.
Materials and methods: This prospective study included 27 patients (mean age 55.59 ± 8.69 years; 59.3% men) with various oncological diseases who developed skin toxicity during antitumor therapy. Symptom severity (xerosis, fissures, eczematization) was assessed using a visual analog scale (VAS) before therapy and after 2 and 4 weeks. Patients used La Roche-Posay Lipikar baume AP+M and La Roche-Posay Cicaplast B5+ products for 4 weeks. A repeated-measures one-way single factor analysis of variance (ANOVA) with post-hoc pairwise comparisons using the Student’s t-test and Holm’s correction was used to assess the statistical significance of changes in the parameters.
Results: A statistically significant reduction in VAS scores was observed for all assessed symptoms (p<0.001). The mean VAS score for xerosis decreased from 8.07±1.04 to 1.37±0.49, the VAS score for fissures decreased from 8.04±0.98 to 1.44±0.51, and the VAS score for eczematization decreased from 8.41±1.12 to 1.37±0.49. Pairwise comparisons between all timepoints also showed statistically significant differences (p<0.001).
Conclusion: The use of La Roche-Posay moisturizing and restorative products has demonstrated high efficacy in the treatment of skin toxicity, leading to a significant and clinically significant reduction in the manifestations of xerosis, fissures, and eczematization in cancer patients undergoing antitumor treatment. 

For citations: Kruglova L.S., Zhuravlev S.V., Shatokhina E.A., Gryazeva N.V. Efficacy of La Roche-Posay products in the treatment of skin toxicity induced by antitumor therapy: a prospective study. Pharmateca. 2025;32(10):92-96. (In Russ.). DOI: https://dx.doi.org/10.18565/pharmateca.2025.10.92-96

Authors’ contribution: L.S. Kruglova – study concept and design, overall project management, results interpretation, preparation and editing of the final manuscript, approval of the final version of the article for publication. N.V. Gryazeva – data collection and analysis, statistical processing of results, data visualization (tables, graphs), preparation of the initial draft of the manuscript, participation in text editing.
Conflicts of interest: The authors confirm that they have no conflicts of interest to declare.
Funding: The study was conducted without any sponsorship.
Patient Consent for Publication: All patients provided informed consent for the publication of their data.
Authors’ Data Sharing Statement: The data supporting the findings of this study are available upon request from the corresponding author after approval from the principal investigator.

Keywords

About the Authors

Larisa S. Kruglova, Dr. Sci. (Med.), Professor, Head of the Department of Dermatovenereology and Cosmetology, Rector, Central State Medical Academy of the Administrative Directorate of the President of the Russian Federation, Moscow, Russia; kruglovals@mail.ru, ORCID: https://orcid.org/0000-0002-5044-5265 (corresponding author)
Sergey V. Zhuravlev, Cand. Sci. (Med.), Chief Physician, Clinical Hospital No. 1 (Volynskaya) of the Presidential Administrative Department of the Russian Federation, Moscow, Russia; volynka@volynka.ru, ORCID: https://orcid.org/0000-0003-4187-1075
Evgeniya A. Shatokhina, Dr. Sci. (Med.), Professor of the Department of Dermatovenereology and Cosmetology, Central State Medical Academy of the Presidential Administrative Department of the Russian Federation; Leading Researcher, Medical Research and Educational Institute, Lomonosov Moscow State University, Moscow, Russia; e.a.shatokhina@gmail.com, ORCID: https://orcid.org/0000-0002-0238-6563
Natalia V. Gryazeva, Dr. Sci. (Med.), Professor, Department of Dermatovenereology and Cosmetology, Central State Medical Academy of the Administrative Directorate of the President of the Russian Federation, Moscow, Russia; tynrik@yandex.ru, ORCID: https://orcid.org/0000-0003-3437-5233

Similar Articles